• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
Sep 30 2022

Mini Budget – A Nice surprise!

Whilst the mini budget from our new Chancellor Kwasi Kwatereng certainly was not mini from the headline grabbing point of view, there were some absolute gems in there for SEIS and EIS investors.  

For EIS and SEIS investors, the Chancellor provided certainty that the schemes would extend beyond the sunset clause of 2025. This provides positive assurance for our employees and investors that we can continue investing into high growth biotechnology companies beyond 2025.  

In addition, for SEIS investors, from April 2023 our SEIS fund can invest upto £250K in a company. This is an increase of two thirds, while the gross asset limit will be increased to £350,000.  Investors will also be able to invest £200,000 into SEIS investments per year, an increase from £100,000. A very positive direction of travel for investors in British Innovation. 

o2h Ventures – Best EIS Investment Manager

The Growth Investor Awards is one of the key events in the o2h Ventures diary.  Although we are recent entrants into the tax efficient space (2018), we have been selected as a finalist for the Best Investment Manager of the Year 2022. We are up against industry veterans such as Parkwalk, Guinness, Par Equity, and Mercia. We hope that our niche biotech investment expertise wins us the award, but if not, we are just happy to be there! Awards Date: 24th November 2022.

Best EIS Investment Manager

 

o2h Ventures Portfolio Survey Results

We have now invested in 28 companies, and we decided to survey our  portfolio. We were genuinely surprised by the results fifty percent of our companies were led by females or had female chairs (this was not by design but just by investing in the best talent).We are early investors, but our companies have raised a total of £230 million and employ 425 people, most of whom will be highly skilled. Please take note, Rt Hon Elizabeth Truss, and continue to support the biotech sector with highly skilled jobs, growth, mega inward investment, and innovations with global patents!

https://o2hventures.com/wp-content/uploads/2022/09/Linkedin-Post-2.mp4

Upcoming Investments

The pipeline of investment opportunities is strong and offers attractive valuations. We are currently planning investments into two deals taking up our pre-emption, firstly into PharmEnable, being led by two blue-chip pharma industry funds and Kuano, having been awarded approximately £400K of non-dilutive funds through a competitive competition. .  

Portfolio in the News! 

Sentinel Oncology announced a worldwide license agreement with PharmaEngine for a small molecule Chk1 inhibitor.  Small Pharma successfully enrolled for phase II a clinical trial. Neurofenix closed a $7M Series A investment round. Phoremost won the Business Weekly Awards 2022’s “Life Sciences Scale-up” honor.  Alevin Therapeutics announced as a finalist for the OBN Awards 2022 for Best Biotech Start-up company, winner announced 17 November 2022.  Neucruit was selected as one of the ten world-leading startups to enter the final stage of the P4 Precision Medicine Accelerator.

Biotech Bikers

We had a great time hosting the Biotech Bikers event. It was wonderful to share a summer bike ride with 50 our portfolio, investors, and collaborators. Let us know if you are interested in coming to the next one!

KI Fund Close on 31st October 2022.

We received approval from HMRC for the o2h human health KI EIS Fund IV with a closing date of 31st October 2022. Please click here or just send a short note to invest@o2h.com and we will schedule a call accordingly to onboard or top-up.

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
related stories
  • o2h Ventures deals pipeline, Knowledge-intensive EIS Fund closing on 5th April 2023 1 March, 2023
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events 1 November, 2022
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates 30 September, 2022
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • o2h Ventures deals pipeline, Knowledge-intensive EIS Fund closing on 5th April 2023
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)